drugset
drugset / Trial / NCT06598969

TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT06598969 ↗

Phase 2 Not yet recruiting 58 enrolled Andalusian Public Foundation for Health Research in Seville
NaSingle-groupOpen-labelOther

Summary

Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.

Timeline

Start
2024-12-30
Primary completion
2026-12-30
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified — —
Background Etoposide Small molecule — —

Indications

acute myeloid leukemia myelodysplastic syndrome